Clinical characteristics and management of hypertense patients diagnosed of heart failure in primary health care in Spain. HICAP Study;Características clínicas y manejo de pacientes hipertensos con diagnóstico de insuficiencia cardíaca en Atención Primaria en España. Estudio HICAP

Revista Clinica Espanola

Volumn 208, Issue 3, 2008, Pages 124-129

  Divison J A ^a,e   De Rivas, B ^b   Marquez Contreras E ^c   Sobreviela, E ^b   Luque, M ^d  

^a Primary Care Center   (Spain)

^b ASTRAZENECA   (United Kingdom)

^c Centro de Salud La Orden   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e Hospital San Carlos ^*  (Spain)

Author keywords

Diagnosis; Heart failure; Hypertension; Treatment

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BLOOD EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIMARY HEALTH CARE; SPAIN;

EID: 42549115860     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1157/13115819     Document Type: Article

References (35)

1. Conthe P. La insuficiencia cardiaca en el siglo XXI. Med Clin (Barc). 2001;2Supl3:1-2.
2. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol. 1993;22:6-13.
3. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J. 1997;18:208-25.
4. McMurray JJV, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19Suppl1:9-16.
5. González Juanatey JR, Alegría Ezquerra EA, Lozano Vidal JV, Llisterri Caro JL, Acuna GJ, González Maqueda I. Impacto de la hipertensión en las enfermedades del corazón en España. Rev Esp Cardiol. 2001;54:139-49.
6. Steward S, Jenkins A, Buchan S, McGuirre A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002;4:361-71.
7. Wenger NK. Cardiovascular disease in the elderly. Curr Probl Cardiol. 1992;16:615-90.
8. Martínez-Selles M, García Robles JA, Prieto L, Serrano JA, Muñoz R, Frades E et al. Annual rates of admission and sensorial variations in hospitalizations for heart failure. Eur J Heart Fail. 2002;4:779-86.
9. Rodríguez-Artalejo F, Guallar-Castillón P, Banegas Banegas JR, del Rey Calero J. Trends in hospitalization and mortality for heart failure in Spain, 1980-1993. Eur Heart J. 1997;18:1771-9.
10. Rodríguez-Artalejo F, Banegas JR, Guallar-Castillón P. Epidemiología de la insuficiencia cardiaca. Rev Esp Cardiol. 2004;57:163-70.
11. Cleland JG, Gemmell I, Khand A. Is the prognosis of heart failure improving? Eur J Heart Fail. 1999;1:229-41.
12. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-40.
13. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation. 2005;112:154-235.
14. Gérvas J y Seminario de información 2005. Potenciar la Atención Primaria para mejorar el seguimiento de la insuficiencia cardiaca en los países desarrollados. Aten Primaria. 2006;37:457-9.
15. Rutten FH, Grobbee DE, Hoes AW. Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. Eur J Heart Fail. 2003;5:337-44.
16. Cleland JGF, Cohen-Soal A, Cosin Aguilar J. Management of heart failure in primary care (the IMPROVEMENT of heart failure programme): an international survey. Lancet. 2002;360:1631-9.
17. Guidelines Committee 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
18. Llisterri JL, Rodríguez Roca GC, Alonso FJ, Lou S, Divisón JA, Santos JA, et al. Control de la presión arterial en población hipertensa española atendida en Atención Primaria. Estudio PRESCAP 2002. Med Clin (Barc). 2004;122:165-71.
19. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J. 1999;20:447-55.
20. Davies M, Hobbs F, Davis R, Kenkre J, Roalfe AK, Hare R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening Study: a population based study. Lancet. 2001;358:439-44.
21. Nielssen OW, Hilden J, Larsen CT, Hansen JF. Cross sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk. Heart. 2001;86:172-8.
22. Barrios Alonso V, Pena Pérez G, González Juanatey JR, Alegría Ezquerra E, Lozano Vidal JV, Llisterri Caro JL, et al. Hipertensión e insuficiencia cardiaca en consultas de Cardiología y Atención Primaria en España. Rev Clin Esp. 2003;203: 334-42.
23. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev. 2000;5:167-73.
24. Haider AW, Larson MG, Franklin SS, Levy D: Framingham Heart Study. Systolic blood pressure, diastolic blood pressure and pulse pressure as predictor of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2003;138:10-6.
25. st century? Heart. 2003;89:49-53.
26. Salvador MJ, Sebaoun A, Sonntag F, Blanch P, Silber S, Aznar J, et al. Estudio europeo del tratamiento ambulatorio de la insuficiencia cardíaca realizado por cardiólogos. Rev Esp Cardiol. 2004;57:1170-8.
27. Baker DW, Bahler RC, Finkelhor RS, Lauer MS. Screening for left ventriculer systolic dysfunction among patients with risk factors for heart failure. Am Heart J. 2003;146:736-40.
28. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More malignant than cancer? Five year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3:315-22.
29. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-25.
30. Coca A. Evolución del control de la hipertensión en Atención Primaria en España. Resultados del estudio Controlpres 2003. Hipertensión. 2005;22:9-14.
31. Coca A, Dalfó A, Esmatjes E, Llisterri JL, Ordóñez J, Gomis R, et al en representación del grupo PREVENCAT. Tratamiento y control del riesgo cardiovascular en atención primaria en España. Estudio PREVENCAT. Med Clin (Barc). 2006;126:201-5.
32. Bhatia RS, Tu JV, Lee DS, Austin PC, Fany J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population- based study. N Eng J Med. 2006;355: 260-9.
33. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Eng J Med. 2006;355:251-9.
34. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM preserved trial. Lancet. 2003;362:777-81.
35. Khunti K, Hearnshaw H, Baker R, Grimshaw G. Heart failure in primary care: qualitative study of current management and perceived obstacles to evidence-based diagnosis and management by general practitioners. Eur J Heart Fail. 2002;4:771-7.